Abstract：To investigate the susceptibility of influenza B viruses to neuraminidase inhibitors, and analyze the molecular characteristics of neuraminidase (NA) genes in Shandong province during 2017-2018 influenza surveillance year. 18 strains of influenza B viruses (Yamagata-lineage:16, Victoria-lineage:2) isolated in Shandong province during 2017-2018 were selected to test the susceptibility to oseltamivir and zanamivir, with biological resistance experiments. After viral nucleotide was extracted, NA genes were amplified by one-step RT-PCR and then sequenced from both directions. The nucleotide and amino acid sequences were analyzed. Of all 18 influenza B viruses tested, 1 Yamagata-lineage virus showed reduced sensitivity to both oseltamivir and zanamivir with NA gene possessing H274Y amino acid mutation. Other 15 Yamagata-lineage viruses and 2 Victoria-lineage viruses were sensitive to oseltamivir and zanamivir. The majority of the 18 strains of influenza B viruses selected at random were sensitive to NAIs, which indicated that NAIs could be used continually for clinical treatment of patients with influenza. Sustained monitoring of antiviral susceptibility should be emphasized for timely detection of antiviral resistant viruses.
吴巨龙, 孙林, 张圣洋, 宋绍霞, 刘倜, 王显军, 李忠. 山东省2017—2018年B型流感病毒药物敏感性检测及神经氨酸酶基因特征分析[J]. 中国人兽共患病学报, 2019, 35(3): 229-233.
WU Ju-long, SUN Lin, ZHANG Sheng-yang, SONG Shao-xia, LIU Ti, WANG Xian-jun, LI Zhong. Susceptibility to neuraminidase inhibitors and genetic characteristic of neuraminidase of influenza B viruses in Shandong Province during 2017 to 2018. Chinese Journal of Zoonoses, 2019, 35(3): 229-233.
[1] McHardy AC, Adams B. The role of genomics in tracking the evolution of influenza A virus[J]. PLoS Pathog,2009, 5(10). DOI: 10.1371/journal.ppat.1000566 [2] Jackson D, Elderfield RA, Barclay WS. Molecular studies of influenza B virus in the reverse genetics era[J]. J Gen Virol, 2011, 92(Pt 1):1-17. DOI: 10.1099/vir.0.026187-0 [3] Rota PA, Wallis TR, Harmon MW, et al. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983[J]. Virology, 1990, 175(1):59-68. DOI:10.1016/0042-6822(90)90186-U [4] Myers JL, Hensley SE: Oseltamivir-resistant influenza viruses get by with a little help from permissive mutations[J]. Expert Rev Anti Infect Ther, 2011, 9(4):385-388. DOI: 10.1586/eri.11.2 [5] Cardoso Y, Oliveira E, Vasconcelos J, et al. Characteristics of patients with influenza-like illness, severe acture respiratory illness, and laboratory-confirmed influenza at a major children’s hospital in Angola, 2009-2011[J]. J Infect Dis, 2012, 206 Suppl 1:S136-139. DOI: 10.1093/infdis/jis534 [6] Ma C, Soto CS, Ohigashi Y, et al.Identification of the pore-lining residues of the BM2 ion channel protein of influenza B virus[J]. J Biol Chem, 2008, 283(23):15921-15931. DOI: 10.1074/jbc.M710302200 [7] Nguyen HT, Sheu TG, Mishin VP, et al. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays[J]. Antimicrob Agents Chemother, 2010, 54(9):3671-3677. DOI: 10.1128/AAC.00581-10 [8] Okomo-Adhiambo M, Sleeman K, Ballenger K, et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective[J]. Viruses, 2010, 2(10):2269-2289. DOI: 10.3390/v2102269 [9] WHO.Meetings of the WHO working group on surveillance of influenza antiviral susceptibility, Geneva, November 2011 and June 2012[J]. Wkly Epidemiol Rec, 2012, 87(39):369-374. [10] Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase[J]. J Virol, 1993, 67(6):2972-2980. [11] Carr S, Ilyushina NA, Franks J, et al. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer[J]. Pediatr Infect Dis J, 2011, 30(4):284-288. DOI: 10.1097/INF.0b013e3181ff863b [12] Burnham AJ, Baranovich T, Govorkova EA. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance[J]. Antiviral Res, 2013, 100(2):520-534. DOI: 10.1016/j.antiviral.2013.08.023 [13] 黄维娟, 李希妍, 谭敏菊,等. 2013-2014年流感流行季节中国大陆B型流感病毒对NAI的敏感性[J]. 病毒学报, 2015(2):50-54. DOI:10.13242/j.cnki.bingduxuebao.002639 [14] Kurebayashi Y, Takahashi T, Tamoto C, et al. High-efficiency capture of drug resistant-influenza virus by live imaging of sialidase activity[J]. PLoS One, 2016, 11(5):e0156400. DOI: 10.1371/journal.pone.0156400 [15] 李希妍, 黄维娟, 成艳辉, 等. 2014-2015监测年度中国B型流感病毒对神经氨酸酶抑制剂的敏感性[J]. 中华微生物学和免疫学杂志, 2016(10):753-757. DOI:10.3760/cma.j.issn.0254-5101.2016.10.006
2019, Vol. 35 
